Major Inquiry Into EMA Pre-Submission Meetings And Bias Risk Concludes
Executive Summary
The European Ombudsman has recommended how the European Medicines Agency can avoid even the perception that the decisions it takes on marketing authorization applications are influenced by the pre-submission interactions it has with drug developers.